TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

Brief summary (registry, in English)

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

What you commit to

• Study type: Interventional · Phase 4
• Participants enrolled: 8505
• From 31 Oct 2018 to the primary completion date, 31 Jan 2025
• 111 sites in 2 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (111)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Beta-blockers after invasively managed STEMI vs NSTEMI without reduced ejection fraction: a prespecified analysis from the REBOOT trial.Rev Esp Cardiol (Engl Ed) · 2026 · PMID 42034335